Since its founding in 2002, Impact Biologicals Inc. has built its identity around helping biomedical researchers obtain proteins they cannot readily produce themselves. The Wallingford company develops custom recombinant proteins for pharmaceutical, biotech and academic clients, while its prion proteins are particularly associated with RT-QuIC research.